Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShort-Term Debt issuancesShort-Term Debt repayments
Growth Metrics
Income Statement
Others
Ratios

Bio Essence (BIOE) Gains from Investment Securities (2021 - 2024)

Bio Essence has reported Gains from Investment Securities over the past 4 years, most recently at $3812.0 for Q2 2024.

  • For Q2 2024, Gains from Investment Securities changed N/A year-over-year to $3812.0; the TTM value through Dec 2024 reached $800.0, up 700.0%, while the annual FY2025 figure was $800.0, 0.0% changed from the prior year.
  • Gains from Investment Securities for Q2 2024 was $3812.0 at Bio Essence, up from -$3012.0 in the prior quarter.
  • Over five years, Gains from Investment Securities peaked at $1.6 million in Q3 2023 and troughed at -$1.6 million in Q4 2023.
  • A 4-year average of $700.0 and a median of $1700.0 in 2021 define the central range for Gains from Investment Securities.
  • On a YoY basis, Gains from Investment Securities climbed as much as 1586763.0% in 2023 and fell as far as 1586763.0% in 2023.
  • Year by year, Gains from Investment Securities stood at $3300.0 in 2021, then crashed by 96.97% to $100.0 in 2022, then tumbled by 1586763.0% to -$1.6 million in 2023, then surged by 100.24% to $3812.0 in 2024.
  • Business Quant data shows Gains from Investment Securities for BIOE at $3812.0 in Q2 2024, -$3012.0 in Q1 2024, and -$1.6 million in Q4 2023.